Retraction: PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing ehrlich ascites carcinoma (International Journal of Nanomedicine., (2015), 10, (6789-6809), 10.2147/IJN.S79489);PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 6789-6809

  Singh, Madhulika ^a   Bhatnagar, Priyanka ^b   Mishra, Sanjay ^a   Kumar, Pradeep ^b   Shukla, Yogeshwer ^a   Gupta, Kailash Chand ^a,b  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Anticancer; Cisplatin; Nanoparticles; Poly(lactide co glycolide); Tea polyphenols

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYCLIN D1; EPIGALLOCATECHIN GALLATE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYGLACTIN; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THEAFLAVIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIFLAVONOID; CATECHIN; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYPHENOL; TEA;

A549 CELL LINE; ACUTE MONOCYTIC LEUKEMIA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BAX GENE; BCL 2 GENE; BIODEGRADABILITY; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SENSITIZATION; EHRLICH ASCITES TUMOR; ENCAPSULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE FUNCTION; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIFESPAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CARCINOMA; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; THP 1 CELL LINE; TREATMENT DURATION; TUMOR INVASION; TUMOR REGRESSION; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, EHRLICH TUMOR; CELL COUNT; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; KINETICS; METABOLISM; MITOCHONDRION; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TEA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BIFLAVONOIDS; CARCINOMA, EHRLICH TUMOR; CATECHIN; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; FEMALE; FLOW CYTOMETRY; HUMANS; KINETICS; LACTIC ACID; MICE; MITOCHONDRIA; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; POLYGLYCOLIC ACID; POLYPHENOLS; REACTIVE OXYGEN SPECIES; TEA;

EID: 84946549335     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S230533     Document Type: Erratum

References (51)

1. Momekov G, Bakalova A, Karaivanova M. Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity. Curr Med Chem. 2005;12:2177-2219.
2. Kartalou M, Essiqmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23-43.
3. Stewart DJ. Mechanism of resistance to cisplatin and carboplatin. Crit Rev OncolHematol. 2007;63:12-31.
4. Singh M, Bhui K, Singh R, Shukla Y. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci. 2013;93:7-16.
5. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Roj anasakul Y, Nimmannit U. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest. 2009;27:624-635.
6. Singh M, Tyagi S, Bhui K, Prasad S, Shukla Y. Regulation of cell growth through cell cycle arrest and apoptosis in HPV 16 positive human cervical cancer cells by tea polyphenols. Invest New Drugs. 2010; 28:216-224.
7. Singh M, Singh R, Bhui K, Tyagi S, Mahmood Z, Shukla Y. Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor kappa B and Akt activation in human cervical cancer cells. Oncol Res. 2011;19:245-257.
8. Roy P, Nigam N, Singh M, et al. Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice. Invest New Drugs. 2010;28:466-471.
9. Yang WH, Fong YC, Lee CY, et al. Epigallocatechin-3-gallate induces cell apoptosis of human chondrosarcoma cells through apoptosis signal-regulating kinase 1 pathway. J Cell Biochem. 2011;112:1601-1611.
10. Chen X, Li Y, Lin Q, et al. Tea polyphenols induced apoptosis of breast cancer cells by suppressing the expression of survivin. Sci Rep. 2014;4:4416.
11. Singh M, Bhatnagar P, Srivastava AK, Kumar P, Shukla Y, Gupta KC. Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol. 2011;7:202.
12. Periasamy VS, Alshatwi AA. Tea polyphenols modulate antioxidant redox system on cisplatin-induced reactive oxygen species generation in a human breast cancer cell. Basic Clin Pharmacol Toxicol. 2013;112:374-384.
13. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009:14:226-246.
14. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol. 2007;2:203-204.
15. Freitas RA Jr. What is nanomedicine? Nanomedicine. 2005;1:2-9.
16. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long circulating polymeric nanospheres. Science. 1994;263:1600-1603.
17. Ringsdrorf H. Structure and properties of pharmacologically active polymers. JPolym Sci Polymer Symp. 1975;51:135-153.
18. Hu S, Zhang Y. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomedicine. 2010;5:1039-1048.
19. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351:19-29.
20. Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today. 2000;3:163-171.
21. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631-651.
22. Esmaeili F, Hosseini-Nasr M, Malekshahi R, Samadi N, Atyabi F, Dinarvand R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedi-cine. 2007;3:161-167.
23. Swami A, Aggarwal A, Pathak A, et al. Imidazolyl-PEI modified nanoparticles for enhanced gene delivery. Int J Pharm. 2007;335: 180-192.
24. Asadishad B, Vossoughi M, Alamzadeh I. In vitro drug release behaviour and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells. Biotechnol Lett. 2010;32:649-654.
25. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem. 2004;91:232-242.
26. Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009;9:85.
27. Katare YK, Muthukumaran T, Panda AK. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm. 2005;301: 150-160.
28. Vert M, Li S, Garreau H. More about degradation of LA/GA derived matrices in aqueous media. J Control Release. 1991;16:15-26.
29. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release. 2005;101:223-232.
30. Chen CY, Liu TZ, Liu YW, et al. 6-Shogaol (alkanone from ginger) induces apoptotic cell death of human hepatoma p53 mutant Mahlavu subline via an oxidative stress-mediated caspase-dependent mechanism. J Agric Food Chem. 2007;55:948-954.
31. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell. 1995;80:293-299.
32. Fleury C, Mignotte B, Vayssière JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002;84:131-141.
33. Kroemer G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ. 1997;4:443-456.
34. Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs. 2004;13:1327-1338.
35. Kim SB, Kim JS, Lee JH, et al. NF-kB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells. FEBSLett. 2006;580:311-318.
36. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapop-totic gene products and enhancement of apoptosis. Mol Cancer Res. 2008;6:1059-1070.
37. Von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J. In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem. 2008;19:1570-1578.
38. Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemo-prevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009;69:1712-1716.
39. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79:330-338.
40. Yadav VR, Prasad S, Kannappan R, et al. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol. 2010;80:1021-1032.
41. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
42. Bursztajn S, Feng JJ, Berman SA, Nanda AR. Poly (ADP-ribose) polymerase induction is an early signal of apoptosis in human neuroblastoma. Brain Res Mol Brain Res. 2000;76:363-376.
43. Chung YM, Bae YS, Lee SY. Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. Free Radic Biol Med. 2003;34:434-442.
44. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of NF-kB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog. 2005;44:51-59.
45. Baldwin AS Jr. The NF-kB and IkB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
46. Gutteridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785-5799.
47. Perkins ND. The Rel/NF-kB family: friend and foe. Trends Biochem Sci. 2000;25:434-440.
48. Panyama J, Labhasetwara V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55: 329-347.
49. Prasad SB, Giri A. Antitumor effect of cisplatin against murine ascites Dalton’s lymphoma. Indian J Exp Biol. 1994;32:155-162.
50. Banerjee SS, Aher N, Patil R, Khandare J. Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J Drug Deliv. 2012;2012:103973.
51. Yoo JW, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev. 2011;63:1247-1256.